(S1 (S (S (NP (NP (DT The) (NN exposure)) (PP (IN of) (NP (JJ inflammatory) (NNS cells))) (PP (TO to) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (JJ extracellular) (NNS stimuli)))))) (VP (VBZ results) (PP (IN in) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ transcriptional)) (CC and) (ADJP (JJ posttranscriptional))) (NNS events)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP culminate) (PP (IN in) (NP (NP (DT the) (NN production)) (PP (IN of) (NP (NP (JJ pro-inflammatory) (NN mediators.11-14) (NN TNF-alpha)) (VP (VP (VBZ is) (VP (VBN released) (ADVP (RB very) (RB early)) (VP (VBG following) (NP (NN shock))))) (CC and) (VP (VBZ is) (VP (VBN considered) (NP (NP (DT an) (JJ important) (NN mediator)) (PP (IN of) (NP (DT the) (JJ inflammatory) (NN cascade)))))))))))))))))) (, ,) (SBAR (IN since) (S (NP (PRP it)) (VP (VBZ regulates) (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (NP (NP (JJ several) (JJ other) (JJ critical) (NNS cytokines)) (CC and) (NP (NN chemokines.15))) (NP (NP (NP (DT A) (JJ clear) (NN relationship)) (PP (IN between) (NP (VBN increased) (NN TNF-alpha) (NN synthesis)))) (CC and) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN shock))))))))))))) (CC and) (S (NP (JJ multiple) (NN organ) (NN dysfunction)) (VP (VBZ has) (VP (VBN been) (VP (VBN observed) (PP (IN in) (NP (NP (NN animal) (NNS models)) (PP (IN of) (NP (NN sepsis.15-17)))))))))))
(S1 (S (S (PP (IN Because) (PP (IN of) (NP (NP (PRP$ its) (NN importance)) (PP (IN in) (S (VP (VBG orchestrating) (NP (NP (JJ multiple) (NNS steps)) (PP (IN of) (NP (DT the) (JJ inflammatory) (NN response)))))))))) (, ,) (NP (NP (NNS strategies)) (VP (VBN aimed) (PP (IN at) (S (VP (VP (VBG decreasing) (NP (NN TNF-alpha) (NNS levels))) (CC or) (VP (VBG attenuating) (NP (PRP$ its) (NN production)))))))) (VP (VBP seem) (ADJP (JJ attractive)))) (. .)))
(S1 (S (S (NP (NN PDE) (NNS inhibitors)) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (VP (TO to) (VP (VB downregulate) (NP (NP (NN TNF-alpha) (NN production)) (PP (IN in) (NP (JJ distinct) (JJ human) (NN cell) (NNS populations))))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN shown) (SBAR (SBAR (IN that) (S (, ,) (PP (IN in) (NP (JJ general))) (, ,) (NP (NN TNF-alpha) (NNS levels)) (VP (VBP continue) (S (VP (TO to) (VP (VB increase) (PP (IN after) (NP (NN LPS) (NN exposure))))))))) (CC and) (SBAR (IN that) (S (NP (NP (JJ concomitant) (NN infusion)) (PP (IN of) (NP (NN phosphodiesterase) (NNS inhibitors)))) (VP (MD can) (ADVP (RB markedly)) (VP (VB decrease) (NP (NP (NN TNF-alpha) (NN levels.18-19)) (S (PP (IN In) (NP (DT this) (ADJP (FW in) (FW vitro)) (NN study))) (, ,) (NP (PRP we)) (VP (VBD verified) (NP (NP (DT the) (JJ sustained) (NN attenuation)) (PP (IN of) (NP (JJ LPS-induced) (NN TNF-alpha) (NN expression)))) (PP (IN over) (NP (NN time))) (PP (IN in) (NP (DT an) (VBN isolated) (JJ human) (JJ mononuclear) (NN cell) (NN population)))))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS mechanisms)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NP (NN PTX)) (, ,) (NP (DT a) (JJ non-specific) (NN phosphodiesterase) (NN inhibitor)) (, ,)) (ADVP (ADVP (RB significantly)) (CC and) (ADVP (RB consistently))) (VP (VBZ decreases) (NP (NN TNF-alpha) (NN production)))))) (VP (VBP have) (RB not) (VP (VBN been) (ADVP (RB completely)) (VP (VBN elucidated))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ has) (VP (VBN been) (VP (VBN postulated) (SBAR (IN that) (S (NP (NP (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (VBP increase) (NP (JJ intracellular) (NN cAMP)))))) (VP (VBP exert) (NP (PRP$ their) (JJ anti-inflammatory) (NNS effects)) (PP (IN through) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN PKA)))))))))))) (. .)))
(S1 (S (S (S (NP (DT This) (JJ classic) (NN pathway)) (VP (VBZ has) (VP (VBN been) (VP (VBN challenged) (PP (IN as) (NP (NP (DT the) (JJ sole) (NN mechanism)) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (NN modulation)) (PP (IN of) (NP (NN inflammation))) (PP (IN by) (NP (JJ cAMP-enhancing) (NNS drugs)))))))))))) (, ,) (CC and) (S (NP (NP (JJ alternative) (NNS mechanisms)) (VP (VBG involving) (NP (JJ PKA-independent) (NNS pathways)))) (VP (VBP have) (VP (VBN been) (NP (NP (NN proposed.6-8)) (S (PP (IN In) (NP (NP (DT this) (NN series)) (PP (IN of) (NP (NNS experiments))))) (, ,) (NP (PRP we)) (VP (VBD observed) (NP (NP (DT a) (JJ significant) (NN attenuation)) (PP (IN of) (NP (NN TNF-alpha) (NN production))) (PP (IN in) (NP (JJ LPS-stimulated) (JJ human) (JJ mononuclear) (NNS cells)))) (PP (VBG following) (NP (NN PTX) (NN administration))) (, ,) (ADVP (JJ independent) (PP (IN of) (NP (NN PKA) (NN activation))))))))))) (. .)))
(S1 (S (NP (PRP We)) (VP (VBD used) (NP (NP (NP (DT a) (JJ nonspecific) (NN phosphodiesterase) (NN inhibitor)) (, ,) (NP (NN PTX)) (, ,)) (PP (IN in) (NP (DT the) (JJ present) (NN study)))) (SBAR (IN because) (S (NP (PRP it)) (VP (VBZ has) (VP (VBN been) (VP (VBN used) (ADVP (RB clinically)) (SBAR (IN in) (S (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (NNS conditions)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN inflammation)) (VP (VBZ is) (NP (NP (DT an) (JJ important) (NN component)) (PP (IN of) (NP (NP (DT the) (NN pathophysiology)) (PP (IN of) (NP (DT the) (NN disease) (NN process.19))))) (S (ADVP (RB Additionally)) (, ,) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NN PTX))) (PP (IN in) (NP (NN sepsis))) (PP (IN as) (NP (NP (DT an) (NN adjunct)) (PP (TO to) (NP (JJ other) (NNS treatments)))))) (VP (TO to) (VP (VB maintain) (NP (JJ adequate) (NN organ) (NN function)))))))))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN explored) (PP (VBN based) (PP (IN upon) (NP (NP (PRP$ its) (NNS effects)) (PP (IN on) (NP (NN TNF-alpha) (NN synthesis))))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB However)) (, ,) (NP (NP (DT the) (VBN reported) (JJ beneficial) (NNS effects)) (PP (IN of) (NP (NN PTX)))) (VP (VBP are) (RB not) (ADJP (RB only) (JJ related) (PP (TO to) (NP (NP (DT the) (NN downregulation)) (PP (IN of) (NP (NP (NN TNF-alphabut)) (PP (ADVP (RB also)) (TO to) (NP (NP (NN PTX) (POS 's) (JJ hemorrheologic) (NNS properties)) (, ,) (NP (PRP$ its) (NN ability) (S (VP (TO to) (VP (VB reduce) (NP (NN neutrophil) (NN activation)))))) (, ,) (CC and) (NP (NP (PRP$ its) (JJ beneficial) (NNS effects)) (PP (IN on) (NP (NP (NN microcirculation)) (, ,) (NP (JJ cardiac) (NN performance)) (, ,) (CC and) (NP (NP (NN organ) (NN injury.20-25)) (S (ADVP (RB Herein)) (, ,) (NP (PRP we)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NP (DT the) (JJ downregulatory) (NNS effects)) (PP (IN of) (NP (NN PTX))) (PP (IN in) (NP (JJ human) (JJ mononuclear) (NNS cells)))) (VP (VBZ involves) (NP (NP (NN modulation)) (PP (IN of) (NP (NP (NNS pathways)) (SBAR (WHNP (WDT that)) (S (VP (VBP involve) (NP (NP (NP (NN NF-kappaB)) (CC and) (NP (NN CREB))) (, ,) (NP (NP (CD two) (JJ major) (NN transcription) (NNS factors)) (VP (VBN involved) (PP (IN in) (NP (DT the) (JJ inflammatory) (NN cascade)))))))))))))))))))))))))))))) (. .)))
(S1 (S (S (NP (NN NF-kappaB/Rel)) (VP (VBZ constitutes) (NP (NP (DT a) (NN family)) (PP (IN of) (NP (NP (JJ transcriptional) (NNS factors)) (VP (VBN involved) (PP (IN in) (NP (NP (NP (DT the) (NN regulation)) (PP (IN of) (NP (JJ numerous) (NN cytokine) (NNS genes)))) (CC and) (NP (NP (JJ immune) (NNS responses)) (PP (IN in) (NP (JJ different) (NN cell) (NNS populations)))))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (ADJP (RBS most) (JJ abundant)) (NN form)) (PP (IN of) (NP (NN NF-kappaB)))) (VP (VBZ is) (NP (NP (DT the) (NN p50-p65) (NN heterodimer.26)) (S (NP (NP (DT The) (JJ inactive) (NN form)) (PP (IN of) (NP (NN NF-kappaB)))) (VP (VBZ exists) (PP (IN in) (NP (NP (DT the) (NN cytoplasm)) (VP (VBD bound) (PP (TO to) (NP (NP (DT an) (JJ inhibitory) (NN complex)) (VP (VBG containing) (NP (NN I-kappaBalpha))))))))))))) (. .)))
(S1 (S (PP (VBG Following) (NP (NP (JJ cellular) (NN stimulation)) (PP (IN with) (NP (NP (NN LPS)) (CC and) (NP (JJ chemotactic) (NNS factors)))))) (, ,) (NP (NN NF-kappaB) (JJ inducible) (NN kinase)) (VP (VP (VBZ phosphorylates)) (CC and) (VP (VBZ activates) (NP (NP (DT the) (NP (NP (NN I-kappaB) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN IKK)) (-RRB- -RRB-))) (NN complex)) (VP (VBG consisting) (PP (IN of) (NP (NP (NN IKK-1)) (CC and) (NP (NN IKK-2))))) (, ,) (SBAR (WHNP (WDT which)) (S (PP (IN in) (NP (NN turn))) (VP (VBZ phosphorylates) (NP (DT the) (NN I-kappaBalpha) (NN subunit)))))))) (. .)))
(S1 (S (S (NP (NP (NP (NN Phosphorylation)) (, ,) (NP (NN ubiquitination)) (, ,) (CC and) (NP (JJ subsequent) (NN degradation))) (PP (IN of) (NP (NN I-kappaBalpha)))) (VP (VBZ results) (PP (IN in) (NP (NN NF-kappaB) (JJ nuclear) (NN translocation))))) (. .)))
(S1 (S (S (NP (DT This)) (VP (VBZ allows) (NP (NP (DT the) (NN transcription) (NN factor)) (S (VP (TO to) (VP (VP (VB bind) (PP (TO to) (NP (NP (NN promoter) (NNS regions)) (PP (IN of) (NP (JJ specific) (JJ pro-inflammatory) (NNS genes)))))) (CC and) (VP (VB influence) (NP (NN transcription.27,28)) (SBAR (IN Because) (S (NP (NP (DT a) (NN number)) (PP (IN of) (NP (JJ potential) (NN kappaB) (NNS sites)))) (VP (VBP are) (ADJP (JJ present) (PP (IN in) (NP (NP (DT the) (NN nucleotide) (NNS sequences)) (PP (IN of) (NP (DT the) (NN TNF-alpha) (NN gene)))))))))))))))) (, ,) (S (NP (NN NF-kappaB)) (VP (VBZ is) (VP (VBN considered) (S (VP (TO to) (VP (VB be) (NP (NP (DT a) (JJ critical) (JJ transcriptional) (NN factor)) (VP (VBN involved) (PP (IN in) (NP (NP (NN TNF-alpha) (NN gene) (NN expression)) (CC and) (NP (NN protein) (NN synthesis.29,30))))))))))))))
(S1 (S (PP (IN In) (NP (NP (DT this) (NN set)) (PP (IN of) (NP (NNS experiments))))) (, ,) (NP (PRP we)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP (NN PTX)) (VP (VBZ downregulates) (NP (NP (NP (JJ cytoplasmic) (NN I-kappaBalpha) (NN phosphorylation)) (, ,) (NP (JJ nuclear) (NN NF-kappaB) (NN p65) (NN phosphorylation/translocation)) (, ,)) (CONJP (RB as) (RB well) (IN as)) (NP (NN NF-kappaB) (NN DNA-binding))) (PP (IN after) (NP (NN LPS) (NN stimulation))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN PTX)) (VP (VBZ exerts) (NP (NP (PRP$ its) (NN function)) (ADJP (JJ proximal) (PP (TO to) (CC or) (PP (IN at) (NP (NP (DT the) (NN level)) (PP (IN of) (NP (NN I-kappaBalpha) (NN phosphorylation))))))))))))))))) (. .)))
(S1 (S (S (NP (NP (JJ Previous) (NNS studies)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN evaluated) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (JJ cAMP-elevating) (NNS drugs))) (PP (IN on) (NP (NP (NN I-kappaBalpha)) (CC and) (NP (NN NF-kappaB)))))))))) (VP (VBP have) (VP (VBN reported) (NP (VBG conflicting) (NNS results))))) (. .)))
(S1 (S (S (NP (NP (NP (NP (NNP Haddad) (FW et) (FW al.)) (VBN reported) (NNS results)) (ADJP (JJ similar) (PP (TO to) (NP (PRP ours))))) (PP (IN with) (NP (NP (NN respect)) (PP (TO to) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NN PTX))) (PP (IN on) (NP (NP (NP (NN I-kappaBalpha)) (CC and) (NP (NN NF-kappaB))) (PP (IN in) (NP (JJ pulmonary) (JJ epithelial) (NN cells.31))))))))) (ADVP (RB Conversely)) (, ,) (NP (NNP Neumann) (FW et) (FW al.))) (VP (VBN proposed) (SBAR (IN that) (S (NP (VBN increased) (JJ intracellular) (NN cAMP)) (VP (VBZ stabilizes) (NP (NP (DT the) (NN interaction)) (PP (IN between) (NP (NP (NN I-kappaBalpha)) (CC and) (NP (NN NF-kappaB))))) (, ,) (S (ADVP (RB therefore)) (VP (VBG reducing) (NP (NP (NN NF-kappaB) (NN activation.32)) (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NNP Takahashi) (FW et) (FW al.)) (VP (VBD showed) (NP (NP (DT no) (NN difference)) (PP (IN in) (NP (NN I-kappaBalpha) (NN degradation))) (PP (IN in) (NP (NN Jurkat) (NNS T-lymphocytes)))) (PP (IN in) (NP (NP (NP (DT the) (NN presence)) (CC and) (NP (NN absence))) (PP (IN of) (NP (NP (NN forskolin)) (, ,) (NP (DT an) (JJ alternative) (NN cAMP) (NN inducing) (NN compound)))))))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN group)) (ADVP (RB also)) (VP (VBD demonstrated) (SBAR (SBAR (IN that) (S (NP (NN forskolin)) (VP (VBD did) (RB not) (VP (VB inhibit) (NP (NP (DT the) (JJ DNA-binding) (NN activity)) (PP (IN of) (NP (NN NF-kappaB)))))))) (CC and) (SBAR (IN that) (S (NP (NN CREB)) (VP (VBD was) (RB not) (VP (VBN involved) (PP (IN in) (NP (NP (JJ forskolin-induced) (NN decrease)) (PP (IN in) (NP (NP (NN p65) (JJ transcriptional) (NN activity.33)) (S (NP (JJ Similar) (NNS results)) (VP (VBD were) (VP (VBN reported) (PP (IN by) (NP (NP (NNP Ollivier) (FW et) (FW al.)) (VP (VBG using) (NP (NP (NP (NN THP-1) (NNS cells)) (CC and) (NP (JJ endothelial) (NNS cells))) (VP (VBN treated) (PP (IN with) (NP (NP (NP (NN forskolin)) (CC or) (NP (NN dibutyryl) (NN cAMP))) (, ,) (NP (NP (CD two) (NNS agents)) (VP (VBN known) (S (VP (TO to) (VP (VB function) (PP (IN through) (NP (NP (NN cAMP) (NN elevation)) (CC and) (NP (NP (JJ subsequent) (NN PKA) (CD activation.9)) (S (NP (NP (DT The) (NNS differences)) (PP (IN between) (NP (NP (PRP$ our) (NNS results)) (CC and) (NP (NP (DT those)) (VP (VBN mentioned) (ADVP (RB above))))))) (VP (MD may) (VP (VB be) (VP (VBN explained) (PP (IN by) (NP (NP (DT the) (NN use)) (PP (IN of) (NP (NP (JJ different) (NN cell) (NNS types)) (CC and) (NP (JJ exogenous) (NNS stimulants))))))))))))))))))))))))))))))))))))))) (. .)))
(S1 (S (S (NP (PRP It)) (VP (VBZ is) (ADVP (RB also)) (ADJP (JJ possible)) (SBAR (IN that) (S (NP (NN PTX)) (VP (VBZ exerts) (NP (PRP$ its) (JJ anti-inflammatory) (NNS effects)) (PP (IN on) (NP (NP (DT the) (NN NF-kappaB) (NN pathway)) (ADJP (JJ independent) (PP (IN of) (NP (NN PKA)))))) (, ,) (SBAR (IN as) (S (VP (VBN suggested) (PP (IN by) (NP (NP (DT the) (JJ continued) (NN attenuation)) (PP (IN of) (NP (NP (JJ LPS-induced) (NN TNF-alpha) (NN production)) (PP (IN by) (NP (NN PTX))) (PP (IN in) (NP (NP (DT the) (NP (NN presence)) (CC or) (NP (NN absence))) (PP (IN of) (NP (NP (NN PKA) (NN inhibition)) (VP (VBN observed) (PP (IN in) (NP (DT this) (NN study)))))))))))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN hypothesis)) (VP (VBZ is) (ADVP (RB currently)) (PP (IN under) (NP (NN investigation))) (PP (IN in) (NP (PRP$ our) (NN laboratory))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (PRP we)) (VP (VP (VBD utilized) (NP (NP (DT a) (JJ broad) (NN PKA) (NN inhibitor)) (PP (IN in) (NP (DT this) (NN study)))) (PP (IN in) (NN addition) (TO to) (NP (NN H89)))) (, ,) (CC but) (VP (VBD did) (RB not) (VP (VB examine) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NP (JJ specific) (NN inhibition)) (PP (IN of) (NP (JJ various) (NN PKA) (NNS isoforms)))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN information)) (VP (MD may) (VP (VB yield) (NP (NP (JJR more) (NN insight)) (PP (IN into) (NP (NP (DT the) (NN mechanism)) (SBAR (WHPP (IN by) (WHNP (WDT which))) (S (NP (NN PTX)) (VP (VBZ exerts) (NP (PRP$ its) (JJ down-regulatory) (NNS effects))))))))))) (. .)))
(S1 (S (S (NP (NN PDE) (NNS inhibitors)) (VP (MD may) (ADVP (RB also)) (VP (VB downregulate) (NP (NN NF-kappaB) (JJ transcriptional) (NN activity)) (PP (IN by) (S (VP (VBG altering) (NP (NP (DT the) (JJ competitive) (NN binding)) (PP (IN of) (NP (NP (NN CREB)) (CC and) (NP (NN NF-kappaB)))) (PP (TO to) (NP (NP (DT the) (NN promoter) (NNS regions)) (PP (IN of) (NP (JJ pro-inflammatory) (NNS genes)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Herein)) (, ,) (NP (PRP we)) (VP (VBD showed) (SBAR (IN that) (S (NP (NP (DT the) (NP (NN activation)) (CC and) (NP (NN DNA) (NN binding) (NN activity))) (PP (IN of) (NP (NN CREB)))) (VP (VBZ is) (VP (VBN upregulated) (PP (IN in) (NP (DT a) (JJ dose-dependent) (NN manner))) (PP (IN by) (NP (NN PTX))))))))) (. .)))
(S1 (S (S (PP (IN Of) (NP (NN note))) (, ,) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN CREB) (NN activity)))) (VP (VBD was) (ADVP (RB slightly)) (VP (VBN alleviated) (PP (IN by) (NP (NP (DT the) (NN addition)) (PP (IN of) (NP (NN LPS)))))) (, ,) (S (VP (VBG suggesting) (NP (NP (NN competition)) (PP (IN between) (NP (NP (JJ PTX-induced) (JJ CREB-associated) (NN gene) (NN transcription)) (CC and) (NP (NP (DT those) (NNS factors)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN NF-kappaB)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB be) (VP (VBN upregulated) (PP (IN by) (NP (NN LPS) (NN exposure)))))))))))))))))) (. .)))
(S1 (S (S (NP (DT This) (NN competition)) (VP (VBZ has) (VP (VBN been) (VP (VBN postulated) (S (VP (TO to) (VP (VB involve) (NP (NP (NP (DT the) (NN recruitment)) (PP (IN of) (NP (DT the) (JJ co-activator) (NN CBP)))) (CC and) (NP (PRP$ its) (NN homologue) (NN p30034)))))))) (, ,) (S (VP (VBG suggesting) (NP (NP (DT an) (JJ alternative) (NN mechanism)) (SBAR (WHNP (WDT that)) (S (VP (MD may) (VP (VB be) (VP (VBN involved) (PP (IN in) (NP (NP (DT the) (JJ anti-inflammatory) (NNS actions)) (PP (IN of) (NP (NN PTX))))))))))))))) (. .)))
(S1 (S (S (NP (JJ Future) (NNS studies)) (VP (VBP are) (VP (VBN planned) (S (VP (TO to) (VP (VB delineate) (NP (NP (DT the) (NN validity)) (PP (IN of) (NP (DT this) (JJ potential) (NN mechanism)))))))))) (. .)))
(S1 (S (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (NN PTX))) (PP (IN on) (NP (NP (JJ other) (NN transcription) (NNS factors)) (, ,) (PP (JJ such) (IN as) (NP (NP (NN AP-1)) (, ,) (NP (NN c-fos)) (, ,) (CC and) (NP (NN c-jun)))) (, ,)))) (VP (MD can) (RB not) (VP (VB be) (VP (VBN ruled) (PRT (RP out)) (PP (IN by) (NP (PRP$ our) (NNS experiments))))))) (. .)))
(S1 (S (S (NP (NP (NN Activation)) (PP (IN of) (NP (NP (NN AP-1)) (CC and) (NP (NP (PRP$ its) (NNS components)) (PRN (-LRB- -LRB-) (NP (NP (NN c-fos)) (CC and) (NP (NN c-jun))) (-RRB- -RRB-))))) (PP (IN by) (NP (NP (NNS agents)) (SBAR (WHNP (WDT that)) (S (VP (VBP enhance) (NP (JJ mononuclear) (NN cell) (NN activity)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN implicated) (PP (IN in) (NP (NN TNF-alpha) (NN expression))))))) (. .)))
(S1 (S (S (ADVP (RB Moreover)) (, ,) (NP (NP (NN AP-1)) (CC and) (NP (NN CREB))) (VP (VBP recognize) (NP (DT a) (JJ similar) (NN DNA) (NN binding) (NN sequence)) (PP (IN in) (NP (NP (DT the) (NN promoter) (NN region)) (PP (IN of) (NP (DT the) (NN TNF-alpha) (NN gene35))))))) (. .)))
(S1 (S (S (PP (IN Given) (NP (DT these) (NNS relationships))) (, ,) (NP (PRP it)) (VP (VBZ is) (ADJP (JJ conceivable) (SBAR (IN that) (S (NP (NN PTX)) (VP (MD may) (VP (VB exert) (NP (NP (DT some)) (PP (IN of) (NP (PRP$ its) (JJ anti-inflammatory) (NNS actions)))) (PP (IN by) (S (VP (VP (VBG affecting) (NP (NN AP-1) (NN activation))) (CC and) (VP (VBG favoring) (NP (NN CREB) (NN binding)))))) (, ,) (S (ADVP (RB thus)) (VP (VBG inhibiting) (NP (NN TNF-alpha) (NN gene) (NN transcription))))))))))) (. .)))
(S1 (S (S (NP (JJ Additional) (NNS studies)) (VP (VBP are) (ADJP (JJ necessary) (S (VP (TO to) (VP (VB elucidate) (NP (NP (DT the) (JJ complex) (NNS interactions)) (PP (IN between) (NP (NP (NP (NN CREB)) (, ,) (NP (NN NF-kappaB)) (, ,) (CC and) (NP (NN AP-1))) (PP (VBG following) (NP (NP (NN LPS) (NN exposure)) (CC and) (NP (NN PDE) (NN inhibition))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN PTX))) (PP (IN on) (NP (NP (DT the) (NN cGMP) (NN pathway)) (PP (IN after) (NP (NN LPS) (NN stimulation)))))) (VP (VBZ has) (RB not) (VP (VBN been) (VP (VBN explored))) (, ,) (SBAR (IN although) (S (NP (PRP we)) (VP (VBD plan) (S (VP (TO to) (VP (VBP do) (ADVP (RB so)) (PP (IN in) (NP (DT the) (JJ future))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN summary))) (, ,) (NP (PRP we)) (VP (VBP have) (VP (VBN demonstrated) (SBAR (IN that) (S (NP (NP (NN PDE) (NN inhibition)) (PP (IN of) (NP (JJ human) (JJ mononuclear) (NNS cells)))) (VP (VBZ downregulates) (NP (NN TNF-alpha) (NN production)) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (PP (IN through) (NP (DT a) (JJ PKA-independent) (NN mechanism))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NN PTX)) (VP (VBZ attenuates) (NP (NP (DT the) (NN activity)) (PP (IN of) (NP (NN NF-B)))) (PP (IN while) (S (VP (VBG upregulating) (NP (NN CREB) (NN activation)) (PP (IN after) (NP (NP (NN LPS) (NN stimulation)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (MD may) (VP (VB result) (PP (IN in) (NP (NP (NN modulation)) (PP (IN of) (NP (JJ pro-inflammatory) (NN mediator) (NN synthesis)))))))))))))))) (. .)))
(S1 (S (S (ADVP (RB Therefore)) (, ,) (NP (NN PTX)) (VP (MD may) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (JJ potential) (NN adjunct) (JJ therapeutic)) (PP (IN for) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (NNS conditions)) (SBAR (WHPP (IN in) (WHNP (WDT which))) (S (NP (NN TNF-alpha) (NN production)) (VP (VBZ plays) (NP (DT a) (JJ significant) (NN role)))))))))))))) (. .)))
